Ann: Quarterly Activities Report, page-2

During the quarter ended 31 March 2020, Biotron Limited (‘Biotron’ or ‘the Company’) has achieved
outcomes including:
 Expanding its antiviral screening program to include SARS-CoV-2, the causative agent of
Covid-19.
 Presentation of new data from the BIT225-009 Phase 2 HIV-1 clinical trial at an international
HIV-1 conference in March 2020.
 Receipt of $753,026 under the R&D Tax Incentive scheme.
SARS-CoV-2
As announced on 6 February 2020, during the quarter, Biotron commenced testing compounds from
its proprietary small molecule compound library for antiviral activity against SARS-CoV-2, the
causative agent of the Covid-19 outbreak.
Biotron has had a long interest in coronaviruses and its scientists were the first to identify and publish
data showing that the E protein of the coronavirus is a viroporin and a good target for antiviral drugs.
Biotron has compounds within its library that have previously demonstrated good antiviral activity
against a range of coronaviruses, including human coronaviruses that cause mild, cold-like symptoms
as well as the coronavirus that was responsible for the outbreak of the SARS virus in 2003.
Importantly, several compounds have broad-spectrum activity against multiple strains of
coronaviruses.
Biotron continues to work with groups within Australia and overseas to assess whether its compounds
can inhibit growth of the new SARS-CoV-2 coronavirus. This work is being done in a careful
methodical, scientifically robust manner which is not a fast process.